Expanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment.
Simulations Plus, Inc. announced the release of ADMET Predictor 13, its machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery.
ADMET Predictor 13 features advancements in three main areas:
- First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations—powered by GastroPlus—combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics.
- Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation.
- Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today’s data-centric R&D teams.
For more information, visit simulations-plus.com.
